Dr. Wael Mohamed, BSc, MMSc, MD, PhD, FAAS, is Professor, Basic Medical Science Department at the International Islamic University Malaysia (IIUM). He specializes in translational brain research and the development of novel treatments for Alzheimer’s Disease and Parkinson’s Disease.

Select Guide Rating

• Section I: Introduction1. Parkinson’s Disease Pathogenesis: From Molecular Insights to Novel Therapies2. Cultural and Regional Considerations in Parkinson’s Pharmacotherapy3. The Tango of Parkinson’s Treatment: The Dance of Balance and Harmony4. Environmental Neurotoxins, Circadian Rhythms and Their Pharmacological Antagonists in Parkinson’s Disease5. Oral Bacteriome Dysbiosis and Mechanisms in Cognitive Impairment among Older People and Parkinson’s Disease: A Systematic ReviewSection II: L-DOPA and DOPAMINERGIC AGENTS6. Dopaminergic Treatments for Parkinson’s Disease: Seeing the Unseen7. Catechol-O-Methyl-Transferase (COMT) Inhibitors: Present Problems and Relevance of the New Ones8. D3 Receptor Agonists and Antagonists as Anti-Parkinsonian Therapeutic Agents9. Non-Dopaminergic TherapiesSection III: EMERGING DRUGS AND TARGETS FOR PARKINSON'S DISEASE10. Management of Motor Symptoms11. Non-Motor Symptoms and Their Pharmacological Management12. Pharmacokinetics and Pharmacodynamics in Parkinson's Disease13. Clinical Case Studies and Practical Applications14. Epigenetic Modulators: Emerging Players in Parkinson’s PharmacotherapySection IV: FUTURE THERAPEUTIC POSSIBILITIES15. Emergent Therapeutic Agents in the Treatment of Parkinson’s Disease16. Future Directions in Parkinson's Disease Pharmacotherapy17. Pioneering The Next Generation Of Therapies18. Genetic Therapies for Parkinson’s Disease: The Dawn of Precision Medicine19. The Gastrointestinal Microbiota and Parkinson’s Disease: What is known and what is still unknown.20. Artificial Intelligence and Machine Learning in Parkinson’s Drug Development21. Repetitive Transcranial Magnetic Stimulation (rTMS) as an Adjunct to Pharmacotherapy in Parkinson’s DiseaseSection V: PHARMACOTHERAPY: HOPES AND HYPES22. Neuroprotective Therapies in Parkinson's Disease23. Polypharmacy and combination therapies in Parkinson’s Disease24. Repurposing Existing Drugs for Parkinson’s Disease Management25. Personalized Medicine andin Parkinson's Disease: Bridging Research and Practice26. Neuroprotective Diets and Their Synergy with PD Pharmacotherapy27. Natural products in the management of Parkinson’s disease in animal modelsSection VI: COGNITIVE NEHANCERS AND PD PHARMACOTHERAPY28. Cognitive Enhancers in Parkinson’s Disease29. Emerging Targets for Cognitive Enhancement30. Artificial Intelligence in PD Pharmacotherapy / Neurostimulation and AI-Augmented Cognitive Therapy31. Personalized Medicine for Cognitive Impairments in PD32. Ethical and Practical Challenges with Cognitive Enhancers33. Unani Pharmacotherapy in the Management of Parkinson’s disease: A Therapeutic Approach34. Music therapy and its synergy with pharmacotherapy in Parkinson’s Disease35. Summary and Conclusion

Dr. Wael Mohamed, BSc, MMSc, MD, PhD, FAAS, is Professor, Basic Medical Science Department at the International Islamic University Malaysia (IIUM). He specializes in translational brain research and the development of novel treatments for Alzheimer’s Disease and Parkinson’s Disease.

Select Guide Rating

• Section I: Introduction1. Parkinson’s Disease Pathogenesis: From Molecular Insights to Novel Therapies2. Cultural and Regional Considerations in Parkinson’s Pharmacotherapy3. The Tango of Parkinson’s Treatment: The Dance of Balance and Harmony4. Environmental Neurotoxins, Circadian Rhythms and Their Pharmacological Antagonists in Parkinson’s Disease5. Oral Bacteriome Dysbiosis and Mechanisms in Cognitive Impairment among Older People and Parkinson’s Disease: A Systematic ReviewSection II: L-DOPA and DOPAMINERGIC AGENTS6. Dopaminergic Treatments for Parkinson’s Disease: Seeing the Unseen7. Catechol-O-Methyl-Transferase (COMT) Inhibitors: Present Problems and Relevance of the New Ones8. D3 Receptor Agonists and Antagonists as Anti-Parkinsonian Therapeutic Agents9. Non-Dopaminergic TherapiesSection III: EMERGING DRUGS AND TARGETS FOR PARKINSON'S DISEASE10. Management of Motor Symptoms11. Non-Motor Symptoms and Their Pharmacological Management12. Pharmacokinetics and Pharmacodynamics in Parkinson's Disease13. Clinical Case Studies and Practical Applications14. Epigenetic Modulators: Emerging Players in Parkinson’s PharmacotherapySection IV: FUTURE THERAPEUTIC POSSIBILITIES15. Emergent Therapeutic Agents in the Treatment of Parkinson’s Disease16. Future Directions in Parkinson's Disease Pharmacotherapy17. Pioneering The Next Generation Of Therapies18. Genetic Therapies for Parkinson’s Disease: The Dawn of Precision Medicine19. The Gastrointestinal Microbiota and Parkinson’s Disease: What is known and what is still unknown.20. Artificial Intelligence and Machine Learning in Parkinson’s Drug Development21. Repetitive Transcranial Magnetic Stimulation (rTMS) as an Adjunct to Pharmacotherapy in Parkinson’s DiseaseSection V: PHARMACOTHERAPY: HOPES AND HYPES22. Neuroprotective Therapies in Parkinson's Disease23. Polypharmacy and combination therapies in Parkinson’s Disease24. Repurposing Existing Drugs for Parkinson’s Disease Management25. Personalized Medicine andin Parkinson's Disease: Bridging Research and Practice26. Neuroprotective Diets and Their Synergy with PD Pharmacotherapy27. Natural products in the management of Parkinson’s disease in animal modelsSection VI: COGNITIVE NEHANCERS AND PD PHARMACOTHERAPY28. Cognitive Enhancers in Parkinson’s Disease29. Emerging Targets for Cognitive Enhancement30. Artificial Intelligence in PD Pharmacotherapy / Neurostimulation and AI-Augmented Cognitive Therapy31. Personalized Medicine for Cognitive Impairments in PD32. Ethical and Practical Challenges with Cognitive Enhancers33. Unani Pharmacotherapy in the Management of Parkinson’s disease: A Therapeutic Approach34. Music therapy and its synergy with pharmacotherapy in Parkinson’s Disease35. Summary and Conclusion

Dr. Wael Mohamed, BSc, MMSc, MD, PhD, FAAS, is Professor, Basic Medical Science Department at the International Islamic University Malaysia (IIUM). He specializes in translational brain research and the development of novel treatments for Alzheimer’s Disease and Parkinson’s Disease.

Select Guide Rating

• Section I: Introduction1. Parkinson’s Disease Pathogenesis: From Molecular Insights to Novel Therapies2. Cultural and Regional Considerations in Parkinson’s Pharmacotherapy3. The Tango of Parkinson’s Treatment: The Dance of Balance and Harmony4. Environmental Neurotoxins, Circadian Rhythms and Their Pharmacological Antagonists in Parkinson’s Disease5. Oral Bacteriome Dysbiosis and Mechanisms in Cognitive Impairment among Older People and Parkinson’s Disease: A Systematic ReviewSection II: L-DOPA and DOPAMINERGIC AGENTS6. Dopaminergic Treatments for Parkinson’s Disease: Seeing the Unseen7. Catechol-O-Methyl-Transferase (COMT) Inhibitors: Present Problems and Relevance of the New Ones8. D3 Receptor Agonists and Antagonists as Anti-Parkinsonian Therapeutic Agents9. Non-Dopaminergic TherapiesSection III: EMERGING DRUGS AND TARGETS FOR PARKINSON'S DISEASE10. Management of Motor Symptoms11. Non-Motor Symptoms and Their Pharmacological Management12. Pharmacokinetics and Pharmacodynamics in Parkinson's Disease13. Clinical Case Studies and Practical Applications14. Epigenetic Modulators: Emerging Players in Parkinson’s PharmacotherapySection IV: FUTURE THERAPEUTIC POSSIBILITIES15. Emergent Therapeutic Agents in the Treatment of Parkinson’s Disease16. Future Directions in Parkinson's Disease Pharmacotherapy17. Pioneering The Next Generation Of Therapies18. Genetic Therapies for Parkinson’s Disease: The Dawn of Precision Medicine19. The Gastrointestinal Microbiota and Parkinson’s Disease: What is known and what is still unknown.20. Artificial Intelligence and Machine Learning in Parkinson’s Drug Development21. Repetitive Transcranial Magnetic Stimulation (rTMS) as an Adjunct to Pharmacotherapy in Parkinson’s DiseaseSection V: PHARMACOTHERAPY: HOPES AND HYPES22. Neuroprotective Therapies in Parkinson's Disease23. Polypharmacy and combination therapies in Parkinson’s Disease24. Repurposing Existing Drugs for Parkinson’s Disease Management25. Personalized Medicine andin Parkinson's Disease: Bridging Research and Practice26. Neuroprotective Diets and Their Synergy with PD Pharmacotherapy27. Natural products in the management of Parkinson’s disease in animal modelsSection VI: COGNITIVE NEHANCERS AND PD PHARMACOTHERAPY28. Cognitive Enhancers in Parkinson’s Disease29. Emerging Targets for Cognitive Enhancement30. Artificial Intelligence in PD Pharmacotherapy / Neurostimulation and AI-Augmented Cognitive Therapy31. Personalized Medicine for Cognitive Impairments in PD32. Ethical and Practical Challenges with Cognitive Enhancers33. Unani Pharmacotherapy in the Management of Parkinson’s disease: A Therapeutic Approach34. Music therapy and its synergy with pharmacotherapy in Parkinson’s Disease35. Summary and Conclusion